The following is a summary of “A prospective feasibility study to differentiate sacral neuromodulation lead electrode configurations using motor and sensory thresholds and locations of sensation,” ...

Boston Scientific has closed on its $3.7 billion acquisition of Axonics. The Marlborough, MA-based company first announced the deal in January. Axonics develops devices to treat urinary and bowel ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ...

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medtronic. The ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Tuesday reported a loss of $19.1 million in its first quarter. On a per-share basis, the Irvine, ...

The Federal Trade Commission (FTC) is taking a closer look at Boston Scientific’s $3.7 billion proposal to acquire neuromodulation developer Axonics, a move that could push back the closing of the ...

According to Axonics, commercial sales of the R20 system in Europe are expected to begin in mid-April. The Axonics fourth-generation rechargeable R20 sacral neuromodulation (SNM) system has been ...

Axonics today announced its R20 rechargeable sacral neuromodulation (SNM) system has received CE Mark approval for use in adults with overactive bladder and/or fecal incontinence. The implant can last ...